BSE Live
Apr 01, 16:00Prev. Close
859.90
Open Price
814.90
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 01, 15:59Prev. Close
859.80
Open Price
814.70
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
859.80 (9924)
| Key Financial Ratios of Ranbaxy Laboratories (in Rs. Cr.) | Mar 14 | Dec 12 | Dec 11 | |
| Per Share Ratios | ||||
| Basic EPS (Rs.) | -20.79 | -3.85 | -72.42 | |
| Diluted EPS (Rs.) | -20.79 | -3.85 | -72.42 | |
| Cash EPS (Rs.) | -14.15 | 0.56 | -65.83 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 25.90 | 45.42 | 45.60 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 25.90 | 45.42 | 45.60 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 162.17 | 149.05 | 184.81 | |
| PBDIT/Share (Rs.) | 10.87 | 16.55 | 30.73 | |
| PBIT/Share (Rs.) | 4.26 | 12.15 | 24.23 | |
| PBT/Share (Rs.) | -20.04 | -3.88 | -72.24 | |
| Net Profit/Share (Rs.) | -20.76 | -3.84 | -72.32 | |
| Profitability Ratios | ||||
| PBDIT Margin (%) | 6.70 | 11.10 | 16.62 | |
| PBIT Margin (%) | 2.62 | 8.15 | 13.11 | |
| PBT Margin (%) | -12.35 | -2.60 | -39.09 | |
| Net Profit Margin (%) | -12.80 | -2.57 | -39.13 | |
| Return on Networth / Equity (%) | 0.00 | 0.00 | 0.00 | |
| Return on Capital Employed (%) | -21.58 | -3.12 | -64.87 | |
| Return on Assets (%) | -6.70 | -1.25 | -21.31 | |
| Total Debt/Equity (X) | 5.46 | 2.48 | 2.02 | |
| Asset Turnover Ratio (%) | 52.38 | 48.60 | 54.45 | |
| Liquidity Ratios | ||||
| Current Ratio (X) | 0.62 | 0.86 | 0.82 | |
| Quick Ratio (X) | 0.43 | 0.63 | 0.65 | |
| Inventory Turnover Ratio (X) | 4.05 | 3.64 | 4.71 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 100.00 | 100.00 | 100.00 | |
| Cash Earnings Retention Ratio (%) | 100.00 | 100.00 | 100.00 | |
| Valuation Ratios | ||||
| Enterprise Value (Cr.) | 20,653.79 | 23,190.83 | 19,047.01 | |
| EV/Net Operating Revenue (X) | 3.01 | 3.68 | 2.44 | |
| EV/EBITDA (X) | 44.87 | 33.13 | 14.69 | |
| MarketCap/Net Operating Revenue (X) | 2.25 | 3.37 | 2.19 | |
| Retention Ratios (%) | 100.00 | 100.00 | 100.00 | |
| Price/BV (X) | 14.09 | 11.07 | 8.89 | |
| Price/Net Operating Revenue | 2.25 | 3.37 | 2.19 | |
| Earnings Yield | -0.06 | -0.01 | -0.18 |
04.05.2020
Book review: ‘Bottle of Lies’ explores Ranbaxy and the unethical underbelly of Indian pharma
01.08.2019
ED raids premises of former Ranbaxy group promoters under PMLA
20.12.2016
Withdraw nod for 28 drug applications of Ranbaxy: Sun Pharma
07.03.2016
Pharma crusader Thakur takes India's drug regulators to court
02.04.2026
02.04.2026
01.04.2026
Buy Granules India; target of Rs 800: Emkay Global Financial
01.04.2026
Granules India shares up 2% after arm gets VAI status post USFDA inspection
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth